Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
tDCS and Sertraline for Depression in Parkinson's Disease
NCT02917122Phase 2Terminated
- Sponsor
- National Cheng Kung University Hospital
- Start
- Aug 2015
- Primary completion
- Aug 2021
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of sertraline in major depressive disorder (MDD), sponsored by National Cheng Kung University Hospital. Primary endpoint: Modified-Unified Parkinson's Disease Rating Scale at 6 weeks. Started Aug 2015; status: terminated.
02
Drugs
sertraline
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02917122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02917122.